HomeCompareARGNF vs CHD

ARGNF vs CHD: Dividend Comparison 2026

ARGNF yields 0.25% · CHD yields 1.27%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CHD wins by $6.3K in total portfolio value
10 years
ARGNF
ARGNF
● Live price
0.25%
Share price
$814.94
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$24.94
Full ARGNF calculator →
CHD
CHD
● Live price
1.27%
Share price
$93.91
Annual div
$1.19
5Y div CAGR
23.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.4K
Annual income
$1,292.51
Full CHD calculator →

Portfolio growth — ARGNF vs CHD

📍 CHD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodARGNFCHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ARGNF + CHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ARGNF pays
CHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ARGNF
Annual income on $10K today (after 15% tax)
$20.86/yr
After 10yr DRIP, annual income (after tax)
$21.20/yr
CHD
Annual income on $10K today (after 15% tax)
$107.94/yr
After 10yr DRIP, annual income (after tax)
$1,098.63/yr
At 15% tax rate, CHD beats the other by $1,077.43/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ARGNF + CHD for your $10,000?

ARGNF: 50%CHD: 50%
100% CHD50/50100% ARGNF
Portfolio after 10yr
$23.2K
Annual income
$658.72/yr
Blended yield
2.84%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARGNF right now

ARGNF
Analyst Ratings
1
Strong
20
Buy
3
Hold
Consensus: Buy
Altman Z
24.1
Piotroski
5/9
CHD
Analyst Ratings
18
Buy
15
Hold
1
Sell
Consensus: Buy
Price Target
$98.40
+4.8% upside vs current
Range: $82.00 — $110.00
Altman Z
4.9
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ARGNF buys
0
CHD buys
0
No recent congressional trades found for ARGNF or CHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricARGNFCHD
Forward yield0.25%1.27%
Annual dividend / share$2.00$1.19
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%23.1%
Portfolio after 10y$20.0K$26.4K
Annual income after 10y$24.94$1,292.51
Total dividends collected$248.00$5.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy

Year-by-year: ARGNF vs CHD ($10,000, DRIP)

YearARGNF PortfolioARGNF Income/yrCHD PortfolioCHD Income/yrGap
1← crossover$10,725$24.54$10,856$156.32$131.00CHD
2$11,500$24.60$11,811$195.24$311.00CHD
3$12,329$24.65$12,883$244.38$554.00CHD
4$13,217$24.70$14,091$306.64$874.00CHD
5$14,167$24.75$15,463$385.88$1.3KCHD
6$15,184$24.79$17,033$487.17$1.8KCHD
7$16,271$24.83$18,843$617.36$2.6KCHD
8$17,435$24.87$20,947$785.72$3.5KCHD
9$18,681$24.90$23,419$1,004.91$4.7KCHD
10$20,013$24.94$26,350$1,292.51$6.3KCHD

ARGNF vs CHD: Complete Analysis 2026

ARGNFStock

argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.

Full ARGNF Calculator →

CHDConsumer Staples

Church & Dwight Co., Inc. develops, manufactures, and markets household, personal care, and specialty products. It operates through three segments: Consumer Domestic, Consumer International, and Specialty Products Division. The company offers cat litters, carpet deodorizers, laundry detergents, and baking soda, as well as other baking soda based products under the ARM & HAMMER brand; condoms, lubricants, and vibrators under the TROJAN brand; stain removers, cleaning solutions, laundry detergents, and bleach alternatives under the OXICLEAN brand; battery-operated and manual toothbrushes under the SPINBRUSH brand; home pregnancy and ovulation test kits under the FIRST RESPONSE brand; depilatories under the NAIR brand; oral analgesics under the ORAJEL brand; laundry detergents under the XTRA brand; gummy dietary supplements under the L'IL CRITTERS and VITAFUSION brands; dry shampoos under the BATISTE brand; water flossers and replacement showerheads under the WATERPIK brand; FLAWLESS products; cold shortening and relief products under the ZICAM brand; and oral care products under the THERABREATH brand. Its specialty products include animal productivity products, such as MEGALAC rumen bypass fat, a supplement that enables cows to maintain energy levels during the period of high milk production; BIO-CHLOR and FERMENTEN, which are used to reduce health issues associated with calving, as well as provides needed protein; and CELMANAX refined functional carbohydrate, a yeast-based prebiotic. The company offers sodium bicarbonate; and cleaning and deodorizing products. It sells its consumer products through supermarkets, mass merchandisers, wholesale clubs, drugstores, convenience stores, home stores, dollar and other discount stores, pet and other specialty stores, and websites and other e-commerce channels; and specialty products to industrial customers and livestock producers through distributors. The company was founded in 1846 and is headquartered in Ewing, New Jersey.

Full CHD Calculator →
📬

Get this ARGNF vs CHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ARGNF vs SCHDARGNF vs JEPIARGNF vs OARGNF vs KOARGNF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.